

1 **SARS-Cov-2 cysteine-like protease (Mpro) is immunogenic and can be detected in**
2 **serum and saliva of COVID-19-seropositive individuals**

3

4 Pedro Martínez-Fleta^a, Arantzazu Alfranca^{a,b}, Isidoro González-Álvaro^{a,c}, Jose M
5 Casanovas^d, Daniel Fernández-Soto^e, Gloria Esteso^e, Yaiza Cáceres-Martell^e, Sofía
6 Gardeta^e, Salomé Prat^d, Tamara Mateu-Albero^a, Ligia Gabrie^a, Eduardo López-Granados^f,
7 Francisco Sánchez-Madrid^{a,b}, Hugh T. Reyburn^{e*}, José M. Rodríguez Frade^{e*}, Mar Valés-
8 Gómez^{e*}

9

10 ***Corresponding authors:** Department of Immunology and Oncology, National Centre for
11 Biotechnology, CNB-CSIC, Madrid, Spain. Tel. +34 91 585 4313; email:
12 mvalés@cnb.csic.es, jmfrade@cnb.csic.es, htreyburn@cnb.csic.es

13

14 **Running title:** SARS-CoV-2 protease antibodies in serum and saliva

15

16 **Keywords**

17 Coronavirus, diagnostics, serology, COVID-19, ELISA

18

19

20 7 Figures, 3 Tables, 4 Supplementary Figures

21

22 This work was supported by the Spanish National Research Council (CSIC, project number
23 202020E079) and grants from Madrid Regional Government “IMMUNOTHERCAN”
24 [S2017/BMD-3733-2 (MVG)]; the Spanish Ministry of Science and Innovation
25 [(MCIU/AEI/FEDER, EU): RTI2018-093569-B-I00 (MVG), SAF2017-82940-R (JMRF),
26 SAF2017-83265-R (HTR); SAF2017-82886-R (FSM)]; RETICS Program of ISCIII
27 [RD16/0012/0006; RIER (JMRF); RD16/0011/0012, PI18/0371 (IGA), PI19/00549 (AA)]. The
28 study was also funded by “La Caixa Banking Foundation” (HR17-00016 to FSM) and Fondo
29 Supera COVID (CRUE-Banco de Santander) to FSM.

30

^a Immunology Department, Hospital Universitario La Princesa IIS-IP, Madrid, Spain

^b CIBER Cardiovascular

^c Rheumatology Department. Hospital Universitario La Princesa. IIS-IP, Madrid, Spain

^d Department of Macromolecular structures, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain CNB

^e Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain

^f Hospital Universitario La Paz, Madrid, Spain

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **Abstract**

32 Currently, there is a need for reliable tests that allow identification of individuals that have been
33 infected with SARS-CoV-2 even if the infection was asymptomatic. To date, the vast majority
34 of the serological tests for SARS-CoV-2 specific antibodies are based on serum detection of
35 antibodies to either the viral spike glycoprotein (the major target for neutralising antibodies) or
36 the viral nucleocapsid protein that are known to be highly immunogenic in other coronaviruses.
37 Conceivably, exposure of antigens released from infected cells could stimulate antibody
38 responses that might correlate with tissue damage and, hence, they may have some value as
39 a prognostic indicator. We addressed whether other non-structural viral proteins, not
40 incorporated into the infectious viral particle, specifically the viral cysteine-like protease, might
41 also be potent immunogens. Using ELISA tests, coating several SARS-CoV-2 proteins
42 produced in vitro, we describe that COVID-19 patients make high titre IgG, IgM and IgA
43 antibody responses to the Cys-like protease from SARS-CoV-2, also known as 3CLpro or
44 Mpro, and it can be used to identify individuals with positive serology against the coronavirus.
45 Higher antibody titres in these assays associated with more severe disease and no cross-
46 reactive antibodies against prior betacoronavirus were found. Remarkably, IgG antibodies
47 specific for Mpro and other SARS-CoV-2 antigens can also be detected in saliva. In
48 conclusion, Mpro is a potent antigen in infected patients that can be used in serological tests
49 and its detection in saliva could be the basis for a rapid, non-invasive test for COVID-19
50 seropositivity.

51

52

53

54

55 INTRODUCTION

56 The identification of the link between a novel beta-coronavirus strain, named
57 Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2), and a fatal
58 respiratory illness, COVID-19, formally recognised as a pandemic by the WHO on
59 March 11 (1, 2) has led to a rush by health systems all over the world to develop and
60 implement testing for viral infection. The rapid cloning and sequencing of the viral
61 genome permitted the development of PCR-based assays for the detection of viral
62 nucleic acids that have become a key strategy for both clinical diagnosis and
63 epidemiological monitoring studies. However, besides identifying individuals with
64 active infection, it is also necessary to know which patients, either symptomatic or
65 asymptomatic, have developed an antibody response to the virus. Several reasons
66 make SARS-CoV-2 serology tests crucial. First, PCR testing is not 100% efficient, (3-
67 5). Second, testing for viral RNA cannot detect evidence of past infection, which will
68 be crucial for epidemiological efforts to assess how many people have been infected
69 in any given area. In addition, this will allow definition of the infection fatality rate and
70 help with management of the epidemic. Third, assays to measure antibody responses
71 and determine seroconversion, while not appropriate to detect acute infections, are
72 however, valuable sources of information on the quality of the response exerted by
73 different individuals developing different clinical manifestations. Moreover, if different
74 isotypes and viral antigens are included in assays testing different time points after the
75 onset of the disease, information of clinical importance will be produced. Finally,
76 quantitative and qualitative assays of antibody responses can aid in the identification
77 of factors that correlate with effective immunity to SARS-CoV-2, the duration of these
78 immune responses and may also aid in the selection of donors from whom
79 preparations of convalescent serum/plasma can be generated for therapeutic use.

80 Multiple antibody tests to detect exposure to SARS-CoV-2, are becoming available.
81 The majority of these assays have been optimised to detect immunoglobulin G (IgG)
82 and, in some cases, IgM antibodies using different viral antigens, being the Spike (S)
83 protein and the nucleoprotein of SARS-CoV-2 the more widely used (6, 7). These
84 proteins are key elements of the viral particle and are expected, by analogy with other
85 coronaviruses, to be highly immunogenic. However, the immunogenicity of other viral
86 proteins, 28 are encoded in the viral genome, has been little explored. Here we have
87 studied the antibody response to the main viral protease (Mpro, or 3CLPro) elicited

88 after viral infection. Although this protein is not exposed in the viral particle, Mpro
89 carries out a critical role in viral replication. Like other beta-coronaviruses, SARS-CoV-
90 2 is a positive-sense RNA virus that expresses all of its proteins as a single polypeptide
91 chain and Mpro cleaves the 1ab polyprotein to yield the rest of the mature proteins of
92 the virus. Since this activity is essential for the viral life cycle, Mpro structure and
93 function has been studied intensively (8); in particular, Mpro has been suggested as a
94 target for specific inhibitors that might act as potent anti-viral agents (9). However, to
95 our knowledge, no study on the antigenicity of this protease has been reported.

96 To increase the possibilities of diagnosing COVID-19 patients, here we report the
97 use of an ELISA test involving the assay of sero-reactivity to three different SARS-
98 CoV-2 antigens, including the protease Mpro. These data demonstrate that individuals
99 who have been infected with SARS-CoV-2 make high titre antibody responses to Mpro
100 and that assays for seroreactivity to this protein sensitively and specifically
101 discriminate between infected and non-infected individuals. Further, while most
102 available tests assess for SARS-CoV-2-specific IgM and IgG antibodies, here, we also
103 explored the presence of IgA antibodies in the sera tested. While, in general, assays
104 for IgM antibodies resulted in a high background that limited the sensitivity of the
105 ELISA, testing for IgA seropositivity provided very clean data, with low background
106 and high signal, therefore providing a very good tool to complement IgG assays.

107 Interestingly, considerable significant amounts of IgA antibodies specific for MPro, as
108 well as the Receptor Binding Domain (RBD) and NP, were also frequently found in
109 serum of COVID-19 infected individuals and the amounts of IgA and IgM antibodies
110 could be related with disease severity.

111 Surprisingly, IgG antibodies specific for SARS-CoV-2 antigens were also readily
112 detectable in the saliva of these patients and, in this case, the titre of protease-specific
113 antibodies was higher than for the other two proteins tested. Since the nasal and
114 buccal mucosa are key sites of viral infection and replication, the presence of
115 antibodies in saliva may be an important feature of the virus-specific immune
116 response, but this observation may also allow the development of a rapid, completely
117 non-invasive assay for COVID-19 seropositivity.

118 **RESULTS**

119

120 **Mpro-specific antibodies can be detected in serum of COVID-19 patients by ELISA**

121 Since this study evaluated, for the first time, whether coronavirus-infected individuals could
122 generate an antibody response against the Cys-like protease, MPro, other SARS-CoV-2
123 proteins, commonly used in serology tests, were produced, for comparison. Mpro and NP were
124 expressed in *E coli*, and two different constructs of the Receptor Binding Domain (RBD) of the
125 spike protein were used: one was expressed by transfection in mammalian cells (mRBD) and
126 a second, produced by baculovirus infection of insect cells (iRBD-His). All the proteins, except
127 mRBD, had a histidine-tag and they were purified on Ni²⁺-NTA columns followed by size
128 exclusion chromatography (Figure 1).

129

130 Before testing a large number of sera from COVID-19 patients and healthy donors,
131 experiments were designed to optimize coating and dilution conditions. These data already
132 revealed that COVID-19 patient sera contained high titres of Mpro-specific antibodies.
133 Antibody reactivity to the viral protease reached saturation at relatively low concentrations and
134 discriminated efficiently between individuals who had been infected with SARS-CoV-2 and
135 those that had not been exposed to the virus (Figure 2A). Serum dilutions from 1/50 to 1/1600
136 covered a broad range of reactivity to Mpro from almost no recognition to saturation (reached
137 at 1/100 dilution). It was also possible to detect low titres of antibodies of the IgM and IgA
138 isotypes in these patients (Figure 2B), suggesting that, in subsequent experiments, a large
139 screening of patient samples should be performed including the three Ig subclasses. Coating
140 titration experiments further confirmed the specificity of the assay (Figure 2C). The IgG
141 reactivity against the protease MPro in COVID-19 patients was comparable, or in certain cases
142 stronger, to the reactivity against RBD, however, no differences were noticed between the
143 RBD recombinant proteins expressed in either mammalian cells or baculovirus
144 (Supplementary Figure 1). These initial experiments suggested that the humoral response
145 against the three viral proteins can be heterogeneous between different patients.

146 To further validate the assay, additional controls were performed such as monitoring the
147 background in plates with no viral antigen coating and testing sera collected before the
148 COVID-19 pandemic (Supplementary Figure 2).

149

150

151

152 **Detection of SARS-CoV-2 Mpro-specific antibodies identifies COVID-19 seropositive**
153 **individuals with high specificity and sensitivity**

154 A cohort of 36 COVID-19 patients (PCR+) and 33 healthy donors was recruited at La Princesa
155 University Hospital, Madrid (Table 1) and ELISA assays were performed to detect Mpro-, as
156 well as RBD- and NP-, specific antibodies of the IgG, IgA and IgM subclasses in sera (Figure
157 3).

158 Titration of the serum samples was carried out over a dilution range of 1/50 to 1/3200, and these
159 experiments showed that assay for seropositivity to all three antigens discriminated between
160 COVID-19 positive and negative donors, as shown in dot plots comparing different dilutions
161 (Supplementary Figure 3). Figure 3 summarises the absorbance data from all the sera samples.
162 To estimate the cut-off value, the sensitivity, and the specificity parameters for each antigen/Ig
163 isotype pair, receiver operating characteristic (ROC) analyses were performed (Table 2, Figure 4).
164 The best area under the curve (AUC) values were obtained with the measurement of IgG
165 antibodies specific for Mpro and NP (AUCs= 0.9945 and 0.9927, respectively). The sensitivity and
166 specificity was above 90% for detection of IgG antibodies of the three proteins tested, with values
167 of sensitivity and specificity for Mpro of 97% and 100% respectively. AUC values above 0.85 were
168 obtained for the other isotypes (IgA, IgM). Measurement of anti-IgA antibodies appeared to
169 discriminate less accurately between pre-COVID-19 sera and COVID-19 sera, however, this is not
170 due to a lack in sensitivity for this isotype. Instead, because background levels with IgA were very
171 low and the signal clearly positive in some patients, the lack of detection suggests that certain
172 COVID-19-positive patients have circulating IgA while other COVID-19-positive patients lack IgA
173 in peripheral blood. Whether the presence of IgA in periphery has any relationship with clinical
174 aspects needs to be explored further in larger cohorts of patients.

175
176 Comparison between proteins showed some heterogeneity in the capacity of different donors to
177 produce antibodies, especially for IgM and IgA subclasses. Non-linear polynomial regression
178 showed a better correlation between the detection of antibodies against NP and Mpro compared
179 to NP and RBD or MPro and RBD (Figure 5A). Only one COVID-19 donor failed to make a full
180 antibody response.

181
182 Further analyses were performed to explore the correlations between the titres of the different
183 antibodies in serum and clinical parameters. Interestingly, a trend for higher titre antibody
184 responses was found in patients with more severe disease (Figure 5B), being more pronounced
185 for IgM against Mpro and IgG against RBD. However, several other variables also contributed to
186 the heterogeneity in antibody response, mainly age and time since the onset of symptoms (Table
187 3). After adjustment for these possibly confounding factors, IgA anti-RBD was observed to be
188 significantly higher in critical patients compared to patients with mild disease. In addition, critical

189 patients showed a trend to higher IgM and IgA anti-Mpro titres than patients with mild COVID-19.
190 Furthermore, intense IgM and IgA responses against the three proteins were significantly
191 associated with higher serum IL-6 levels (data not shown).

192
193 Importantly, in the experiments reported here no SARS-CoV-2-specific antibodies were detected
194 in more than 70 serum samples collected pre-pandemic. However, the majority of these pre-
195 COVID-19 sera did contain antibodies against the nucleoprotein from the related HCoVOC43
196 betacoronavirus, that causes mild common cold-like diseases (Figure 6). Thus these data
197 demonstrate that prior infection with another coronavirus does not seem to lead to the generation
198 of antibodies cross-reactive with the SARS-CoV-2 virus.

199
200 Therefore, the use of SARS-CoV-2 Mpro, in combination with other antigens already described
201 for serology tests, provided outstanding specificity and sensitivity for patient identification. IgG
202 titrated further than IgA or IgM indicating that, as expected, the IgG subclass is more abundant
203 in serum. Assay for IgM antibodies had a lower signal/noise ratio and, in many of the SARS-
204 CoV-2 negative sera a significant background could be observed for IgM. In contrast, SARS-
205 CoV-2-specific IgA antibodies were not detected in healthy donors, but were clearly present
206 in 27 out of the 36 sera tested from COVID-19 patients.

207

208 **Mpro-specific IgG antibodies are detected in saliva from COVID-19 patients**

209 Saliva samples were collected from 11 healthy donors and 12 COVID-19 patients at the
210 University Hospital La Princesa (Madrid) and tested in ELISA assays over a range of
211 dilutions (1/2 to 1/10). IgG recognizing the three viral antigens tested could be observed in
212 COVID-19 patients, with the strongest responses being those specific for the viral protease
213 Mpro (Figure 7). IgA responses were detected in only one of the COVID-19 infected
214 individuals (data not shown).

215

216 DISCUSSION

217 The results presented here describe the detection of antibodies against the SARS-CoV-2
218 protease, Mpro, in serum from COVID-19 patients. The titres of Mpro-specific antibodies were
219 comparable to those produced against SARS-CoV-2 nucleoprotein and somewhat higher than
220 the antibody responses to the RBD fragment of the Spike glycoprotein, both of which are
221 generally considered immunogenic coronavirus proteins. These high titre antibody responses
222 in serum were accompanied by the detection of Mpro-specific IgG antibodies in saliva,
223 providing a new opportunity for completely, non-invasive diagnostic tests.

224 For IgG antibodies in sera, the titres of NP and Mpro-specific antibodies correlate very well
225 with each other ($r=0.94$ y $p<10^{-4}$) and also with anti-RBD responses ($r=0.89$ y $p<10^{-4}$). In
226 contrast, while NP- and Mpro-specific antibody titres also correlate well for IgA and IgM
227 responses (r values greater than 0.9), the correlation with IgM and IgA for RBD is much weaker
228 (r values around 0.6). One plausible possibility is that the antibody responses to internal
229 antigens, Mpro and NP, correlate well, since production of antibodies against these proteins
230 requires either viruses with a broken membrane or release of viral material from infected cells.

231 The correlation with clinical data and symptoms onset reveals that antibodies have higher
232 titres as the severity of the disease increases. Although the sample size is not large, this
233 correlation was significant and independent of age and time from the beginning of symptoms
234 for anti-RBD IgA and almost significant for anti-Mpro IgM and IgA. The retrospective design of
235 our study does not allow to determine whether these increased levels are cause or
236 consequence of more severe disease and what is the basis of its relationship with higher levels
237 of IL-6 detected in critical patients. In this regard, it is surprising that IgM persisted at high
238 levels in patients' sera for more than a month after the beginning of symptoms.

239 The finding that the protease Mpro can be antigenic opens a new series of questions on the
240 biology of this protein that is an important target for the development of antivirals to block
241 SARS-CoV-2 replication. Mpro is key for cleavage and activation of the first polypeptide
242 translated after infection, but the protein has not been found in the virion. So, most probably,
243 the generation of antibodies directed against Mpro occurs at the end of the viral life cycle when
244 intracellular antigens are released from the infected cell. It is not clear whether antibodies
245 specific for Mpro might interfere with viral replication directly, however B cells producing these
246 antibodies would likely efficiently internalise and present this antigen to stimulate T cell
247 recognition of peptides from intracellular proteins.

248 The data presented here also show that, while antibodies for another betacoronavirus,
249 HCoVOC43, were found frequently in pre-COVID19 sera, SARS-Cov-2-specific antibodies were
250 undetectable, demonstrating that infection with one coronavirus does not necessarily prime for a

251 better antibody response to another, at least for the viral antigens tested in these assays.
252 Sequence analysis also suggests that it is unlikely that the response detected against NP and
253 Mpro is due to cross-reactivity between coronavirus-specific antibodies. While COVID-19 Mpro
254 has 96% homology with the main protease of SARS-CoV, which emerged in China in 2003, the
255 similarity with other coronaviruses is much lower. All the samples analysed in this study came from
256 hospitals in Spain, where no cases of SARS-CoV-1 have been reported. The similarity between
257 the Cys-like proteases (Mpro) of different coronaviruses: SARS-CoV-2, HCoVNL63,
258 HCoVOC43 and HCoV229E similarity is only around 40% with changes and similarities
259 distributed along the whole sequence ([Supplementary Figure 4](#)).

260

261 A remarkable observation is that SARS-CoV-2 specific antibodies can be detected in the saliva
262 of seropositive individuals. Two major antibody classes are found in saliva: secretory IgA
263 (SIgA), synthesized locally by plasma cells (PCs) in salivary glands and IgG that is mainly
264 derived from serum via gingival crevices (10). In our experiments salivary SARS-CoV-2
265 antibodies were mainly IgG rather than IgA; only one out of 12 individuals with SARS2-specific
266 IgA was observed, corresponding to a donor that had recovered from the disease one month
267 before the saliva test. The observation that COVID-19-positive, but not COVID-19-negative,
268 individuals contain robustly detectable levels of SARS-CoV-2 NP and Mpro-specific antibodies
269 in saliva is interesting because the development and validation of a saliva-based assay for
270 SARS-CoV-2 seropositivity would represent a practical, non-invasive alternative to blood-
271 based assays for COVID-19 diagnostic testing that might complement saliva-based nucleic
272 acid tests for SARS-CoV-2 nucleic acid.

273

274

275 **METHODS**

276 ***Molecular cloning of the Cys-like protease (Mpro) and nucleocapsid (NP) proteins of*** 277 ***SARS-CoV-2 and the NP of HCoV43***

278 A gene encoding SARS-CoV-2 Mpro from the Wuhan-Hu-1 strain (ORF1ab polyprotein
279 residues 3264-3569, GenBank code:MN908947.3) was amplified by PCR using the oligos 5'-
280 gaccatggcttcagctgttttcagagtgggtt-3' and 5'-gacctcgagttggaaagtaacacctgagcatt-3', digested
281 with NcoI and XhoI and ligated into the vector pET22b (Novagen) linearized with the same
282 restriction enzymes.

283 Oligonucleotides 5'-gatccatggcttctgataatgggtccgcaaaatcagcgaatgca-3' and 5'-
284 caggctgcacaggctctgttggtgggaatg-3' were used to amplify the nucleocapsid protein of SARS-
285 CoV-2. The amplification product was then digested with NcoI and Sall and ligated into the
286 pET26b vector (Novagen) digested with NcoI and XhoI.

287 Oligonucleotides 5'- gatccatggcttcttttactcctggaagcaatcc -3' and 5'-
288 gacctcgagtatttctgaggtgtcttcagtatag -3' were used to amplify the nucleocapsid protein of
289 HCoV43. The amplification product was then digested with NcoI and XhoI and ligated into
290 the pET26b vector (Novagen) digested with NcoI and XhoI.

291 The integrity of all constructs was verified by sequencing at MWG Eurofins.

292 ***Expression of the SARS-CoV-2 Cys-like protease (Mpro) and nucleocapsid (NP)*** 293 ***proteins***

294 Recombinant viral proteins were expressed in the *E. coli* strain BL21 Star (DE3) pLysS
295 (ThermoFisher).

296 SARS-CoV-2 Mpro protein was expressed by transforming this plasmid into the *E. coli*
297 strain BL21 Star (DE3) pLysS. Transformed clones were pre-cultured overnight at room
298 temperature in 50 mL 1 x LB medium with ampicillin (150 µg/mL) and chloramphenicol
299 (34ug/ml). The overnight culture was then inoculated into 1L of 1 x LB medium (150 µg/mL
300 ampicillin and 34ug/ml chloramphenicol) and the culture was grown at 37°C with agitation until
301 the OD₆₀₀ reached 0.6 when Isopropyl-D-thiogalactoside (IPTG) was added to 1mM to induce
302 overexpression of the Mpro gene. The same protocol was followed to produce the
303 nucleocapsid proteins except that kanamycin (150ug/ml) was used instead of ampicillin for
304 antibiotic-mediated selection.

305 After overnight culture at 22°C for NP, 3h at 37°C for Mpro, bacteria were harvested
306 by centrifugation at 9500 x g, 4°C for 15 min and the pellets were washed by resuspension in

307 150 mL TES buffer (20 mM Tris pH 8, 2mM EDTA, 150 mM NaCl) and re-centrifugation.
308 Washed pellets were either processed immediately or stored frozen for later use.

309 Fresh, or thawed, cell pellets were resuspended in ice-cold 50 mM NaH₂PO₄ buffer
310 pH8, 500 mM NaCl, 10 mM imidazole (I2399, Sigma Aldrich), 0.1% Sarkosyl, and 5% glycerol
311 (pH 8.0). Lysozyme was then added (to 0.25 mg/ml) as were phenylmethylsulfonyl fluoride,
312 Leupeptin and Pepstatin A (all to a final concentration of 1mM) and DNase I (2 µg/ml). Bacteria
313 were lysed by sonication (3 cycles of 30 seconds with 30 seconds rest on ice between pulses)
314 and soluble proteins were separated by centrifugation of the lysed cells at 14,000g at 4 °C for
315 45 minutes.

316 6-histidine tagged proteins were purified from the lysate using Nickel Affinity Cartridges
317 5ml (Agarose Bead Technologies S.L.). The bacterial supernatant was loaded on the column
318 at a flow rate of 1 ml/min, followed by washing with 5 column volumes of 50 mM NaH₂PO₄
319 buffer, 500 mM NaCl, 10 mM imidazole and then 5 column volumes of 50 mM NaH₂PO₄ buffer,
320 500 mM NaCl, 25 mM imidazole. Recombinant proteins were eluted using a linear gradient of
321 imidazole ranging from 25 mM to 250 mM over 5 column volumes (a representative SDS-
322 PAGE analysis of the eluted fractions is shown in Supplementary Figure 1A). The proteins
323 were then further purified by gel filtration using a 10/30 Superdex 75 Increase column (Cytiva)
324 pre-equilibrated in 20mM HEPES, 1mM EDTA, 300mM NaCl, pH 7.5. The gel filtration analysis
325 indicated that the SARS CoV 2 Mpro protein purified as a dimer.

326

327 ***Molecular cloning and production of SARS-CoV-2 Receptor Binding Domain protein in*** 328 ***mammalian cells (mRBD)***

329 The cDNA region coding for the Receptor Binding Domain (RBD) (residues 334–528)
330 defined in the structure of the S protein (PDB ID 6VSB) was amplified for expression in
331 mammalian cells. The fragment was cloned in frame with the IgK leader sequence, an HA-
332 tag (YPYDVPDYA) and a thrombin recognition site (LVPRGS) at its 5' end, and it was followed
333 by a second thrombin site, the TIM-1 mucin domain and the human IgG1 Fc region at the 3'
334 end. The recombinant cDNA was cloned in a vector derived from the pEF-BOS (11) for
335 transient expression in HEK293 cells, and in the pBJ5-GS vector for stable protein production
336 in CHO cells following the glutamine synthetase system (12). The inclusion of the TIM-1 mucin
337 domain enhanced protein expression.

338 Mammalian RBD (mRBD) fused to the mucin domain and the Fc region (mRBD-
339 mucin-Fc) was initially purified from cell supernatants by affinity chromatography using an
340 IgSelect column (GE Healthcare). The mucin-Fc portion and the HA-tag were released from

341 the mRBD protein by overnight treatment with thrombin at RT. The mixture was run through
342 a protein A column to remove the mucin-Fc protein and mRBD was further purified by size-
343 exclusion chromatography with a Superdex 75 column in HBS buffer (25 mM HEPES and
344 150 mM NaCl, pH 7.5). The concentration of purified mRBD was determined by absorbance
345 at 280 nm.

346 ***Baculovirus production of RBD-His tagged protein***

347 A recombinant baculovirus expressing the RBD domain was generated using a
348 pFastBac Dual-derived plasmid harboring the RBD coding sequence kindly provided by Dr. F.
349 Krammer (6). HighFive (ThermoFisher Scientific) cell cultures were infected with the
350 recombinant virus at a multiplicity of infection of 3 plaque forming units per cell and maintained
351 in TC-100 medium (ThermoFisher Scientific) for 72 h. Thereafter, cell medium was harvested
352 and clarified by centrifugation (4,300 x g for 10 min) and filtration through a 0.45 µm filter.
353 Supernatant was loaded onto a chelated Nickel Affinity Cartridge-5ml (Agarose Bead
354 Technologies S.L.) at a flow rate of 1.5 ml/min and eluted with a linear gradient of 500 mM
355 Imidazole in Tris-saline buffer pH 7.5. Fractions were analyzed by SDS-PAGE and those
356 containing RBD were pooled together and concentrated using an Amicon Ultra-15 Centrifugal
357 unit with a 10 kDa cutoff membrane (Millipore). The concentrated protein was loaded onto a
358 Superdex 75 10/300 Increase gel-filtration (GE Healthcare) equilibrated with PBS. The peak
359 fractions were analyzed by SDS-PAGE and pooled together for further analysis.

360 ***ELISA for detection of antibodies to SARS-CoV-2***

361 96-well Maxisorp Nunc-Immuno plate were coated with 100 µL/well of recombinant
362 proteins diluted in 0.1 M borate buffered saline (BBS) pH 8.8; NP and the protease at 0.5
363 µg/ml, RBD at 1µg/ml and incubated overnight at 4°C. Coating solutions were then aspirated,
364 the ELISA plates were washed three times with 200 µl of PBS 0.05% Tween 20 (PBS-T) and
365 then dried before blocking with PBS-casein (Biorad, 1x PBS blocker) for 1 hour at room
366 temperature. The plates were washed again with PBS-T and 100 µl of patient serum/plasma
367 sample diluted in PBS-casein, 0.02% Tween-20, as indicated, was added and incubated for 2
368 hours at room temperature. The plates were washed again and 100 µL/well of the indicated
369 detection antibody [(AffiniPure Rabbit Anti-Human IgM, Fc μ fragment specific; AffiniPure
370 Rabbit Anti-Human Serum IgA, α chain specific; AffiniPure Rabbit Anti-Human IgG, Fc γ
371 fragment specific) from Jackson Labs, or anti-human (Fab)'2 HRPO-labelled antibody from
372 Thermo Fisher Scientific] was added and incubated for 1 hour at room temperature. The plates
373 were washed with PBS-T four times and incubated at room temperature in the dark with 100
374 µL/well of Substrate Solution (OPD, Sigma prepared according to the manufacturer's
375 instructions) (typically for 3 minutes). 50 µL of stop solution (3M H₂SO₄) were then added to

376 each well and the optical density (at 492nm) of each well was determined using a microplate
377 reader.

378 Negative controls included wells coated just with blocking buffer and serum samples
379 collected from donors before 2019.

380 **Statistical analysis**

381 Graphics and statistical analysis was performed with Graph Pad Prism 8 Software (GraphPad
382 Software, USA, www.graphpad.com) and Stata 14.0 for Windows (Stata Corp LP, College
383 Station, TX, USA). Quantitative variables following a non-normal distribution were represented
384 as median and interquartile range (IQR) and the Mann Whitney test was used to test for
385 statistically significant differences. Variables with a normal distribution were described by
386 mean±standard deviation (SD) and differences between groups were assessed with Student's
387 t-test. Qualitative variables were described as counts and proportions and χ^2 or Fisher's exact
388 test was used for comparisons. Correlation between quantitative variables was analysed using
389 the Pearson correlation test.

390 Severity of COVID-19 was established as previously described (13). In this case, to determine
391 differences in titres of antibodies between groups of severity the Cuzick's test, that assesses
392 trends across ordered groups, was employed.

393 Since several variables might contribute to differences in ELISA titres, multivariable linear
394 analysis using generalized linear models (glm command of Stata) in which the dependent
395 variable were ELISA titres of each isotype against each protein. The first model included age,
396 gender and time from symptoms onset, followed by backward stepwise approach removing all
397 variables with a p value >0.15 to obtain the best model for each protein and isotype. Then, the
398 variable of interest (severity, anosmia or IL-6 serum levels) was forced in the model.

399 To determine the capacity of the different ELISA to discriminate between pre-COVID-19 sera
400 and those sera obtained from patients with SARS-CoV-2, as determined by positive PCR from
401 nasopharyngeal exudates, ROC analysis was performed, using the roctab command of Stata
402 14.1® (College Station, Texas). Each cut-off point was selected based on the best trade-off
403 values between sensitivity, specificity and the percentage of patients correctly classified. ROC
404 curves and area under curve (AUC) were also obtained.

405

406 **Patient samples and Institutional Review Boards**

407 This study used samples from the research project "Immune response dynamics as predictor
408 of COVID-19 disease evolution. Implications for therapeutic decision-making" [PREDINMUN-

409 COVID] approved by La Princesa Health Research Institute (IIS-IP) Research Ethics
410 Committee (register # 4070). Some experiments included patients from “Study of the
411 lymphocytic response against SARS-COV-2, in different situations of host health and COVID-
412 19 severity (InmunoCOVID)” approved by the Hospital La Paz Committee (HULP: PI-4101).
413 All experiments were carried out following the ethical principles established in the Declaration
414 of Helsinki. All included patients (or their representatives) were informed about the study and
415 gave a written informed consent.

416 **Patient selection**

417 36 COVID-19 patients, diagnosed by PCR, were recruited for the study. 9 of them presented
418 active infection by SARS-CoV2 at the moment of the study whereas the rest had no detectable
419 levels of the virus. 10 patients required hospitalization, of which 6 were admitted to the ICU
420 (Table 1). 33 serum samples from patients presenting a monoclonal gammopathy, allergic
421 disease or rheumatoid arthritis, collected before June 2019 (PRE-COVID-19), were used as
422 negative controls. All samples were stored frozen before use.

423 **Antibody detection in saliva samples**

426 12 donors with high antibody titres in serum were selected to measure specific IgG and IgA
427 against SARS-CoV2 in saliva. For this purpose, new saliva samples were collected from these
428 patients, and also from 11 healthy donors, aliquoted and immediately frozen. Prior to use,
429 saliva samples were thawed, centrifuged at 400g and diluted 1/2, 1/4 and 1/10 in 1x PBS with
430 1% casein (Bio-Rad) and 0.02% Tween-20 supplemented with Complete™ Protease Inhibitor
431 Cocktail (Roche).

432

433

434

435

436

437

438 **Acknowledgements**

439 The authors would like to thank the director of the CNB-CSIC, M. Mellado, for coordination;
440 Luis Enjuanes and Sonia Zúñiga (CNB-CSIC) for SARS-CoV-2 DNA; Florian Krammer (Mount
441 Sinai School of Medicine) for the plasmid for iRBD expression; César Santiago, Antonio J.
442 Varas, Juan R. Rodríguez and José F. Rodríguez (CNB-CSIC) for the production and
443 purification of iRBD. R. Delgado (Hospital 12 de Octubre, Madrid) for sera sample selection.

444

445 **Author contributions**

446 HTR, DFS, GE, YCM, JMC, SP cloned and expressed proteins; JMRF, MVG, AA, PX, FSM,
447 designed and optimized ELISA experiments; YCM, SG, AA, PM, TMA, LG, JMRF, MVG,
448 implemented experiments; ELG, PM, AA, IG, FSM selected patients and performed clinical
449 evaluation; IG, PM carried out statistical analysis; JMRF, MVG, FSM, HTR were responsible
450 for the conception and design of the study and obtaining financial support; JMRF, MV, HTR,
451 FSM, PM, AA wrote the manuscript with revisions from all authors

452 **Conflict of interest**

453 JMRF, JMC, HTR and MVG are inventors on the European patent “Assay for the detection of
454 the Cys-like protease (Mpro) of SARSCoV-2” [EP20382495.8]. IGA had personal fees from
455 Lilly and Sanofi, personal fees and non-financial support from BMS, personal fees and non-
456 financial support from Abbvie, research support, personal fees and non-financial support from
457 Roche Laboratories, non-financial support from MSD, Pfizer and Novartis, not related to the
458 submitted work. The rest of the authors declare no potential conflict of interest.

459

460

461 **REFERENCES**

- 462 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from
463 Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727-33.
- 464 2. Coronaviridae Study Group of the International Committee on Taxonomy of V. The
465 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-
466 nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020;5(4):536-44.
- 467 3. Liu R, Han H, Liu F, Lv Z, Wu K, Liu Y, et al. Positive rate of RT-PCR detection of
468 SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to
469 Feb 2020. *Clin Chim Acta.* 2020;505:172-5.
- 470 4. Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, et al. Quantitative Detection and
471 Viral Load Analysis of SARS-CoV-2 in Infected Patients. *Clin Infect Dis.* 2020.
- 472 5. Wang H, Li X, Li T, Zhang S, Wang L, Wu X, et al. The genetic sequence, origin, and
473 diagnosis of SARS-CoV-2. *Eur J Clin Microbiol Infect Dis.* 2020.
- 474 6. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M,
475 et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat*
476 *Med.* 2020.
- 477 7. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, et al. Serology for
478 SARS-CoV-2: Apprehensions, opportunities, and the path forward. *Sci Immunol.*
479 2020;5(47).
- 480 8. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of
481 SARS-CoV-2 main protease provides a basis for design of improved alpha-
482 ketoamide inhibitors. *Science.* 2020;368(6489):409-12.
- 483 9. Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, et al. Structure-based design of
484 antiviral drug candidates targeting the SARS-CoV-2 main protease. *Science.*
485 2020;368(6497):1331-5.
- 486 10. Brandtzaeg P. Do salivary antibodies reliably reflect both mucosal and systemic
487 immunity? *Annals of the New York Academy of Sciences.* 2007;1098:288-311.
- 488 11. Mizushima S, and Nagata S. pEF-BOS, a powerful mammalian expression vector.
489 *Nucleic Acids Research.* 1990;18(17):5322-.
- 490 12. Casasnovas JM, and Springer TA. Kinetics and thermodynamics of virus binding to
491 receptor. Studies with rhinovirus, intercellular adhesion molecule-1 (ICAM-1), and
492 surface plasmon resonance. *The Journal of biological chemistry.*
493 1995;270(22):13216-24.
- 494 13. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
495 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
496 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*
497 2020. doi: 10.1001/jama.2020.2648

499

500

501

Table 1. Patient demographic and clinical data

| | | N=36 | % | |
|--|------------|-------------|----------|----|
| Gender | Male | 21 | 58 | |
| | Female | 15 | 42 | |
| Age | < 35 | 7 | 19 | |
| | 35-60 | 18 | 50 | |
| | > 60 | 11 | 31 | |
| Time from symptoms onset to sample collection | < 15 days | 2 | 6 | |
| | 15-30 days | 13 | 36 | |
| | 31-45 days | 14 | 39 | |
| | > 45 | 7 | 19 | |
| Hospitalization | Yes | Ward | 4 | 11 |
| | | ICU | 6 | 17 |
| | No | 26 | 72 | |
| Fever | | 31 | 86 | |
| Shivers | | 23 | 64 | |
| Headache | | 22 | 61 | |
| Confusion | | 6 | 17 | |
| Conjunctival congestion | | 5 | 14 | |
| Nasal congestion | | 18 | 50 | |
| Rhinorrhea | | 16 | 44 | |
| Anosmia | | 16 | 44 | |
| Ageusia | | 18 | 50 | |
| Odynophagia | | 14 | 39 | |
| Dry cough | | 19 | 53 | |
| Productive cough | | 9 | 25 | |
| Dyspnea | | 21 | 58 | |
| Chest pain | | 12 | 33 | |
| Tonsillitis | | 3 | 8 | |
| Adenopathies | | 4 | 11 | |
| Nausea/vomiting | | 10 | 28 | |
| Diarrhea | | 16 | 44 | |
| Skin rash | | 2 | 6 | |
| Acrocyanosis | | 1 | 3 | |
| Myalgia/arthralgia | | 24 | 67 | |
| Asthenia | | 27 | 75 | |
| Weight loss | | 20 | 56 | |
| Thrombotic events | | 2 | 6 | |
| Comorbidities (HTN, DM, COPD, obesity, cancer) | | 17 | 47 | |

502 ICU (intensive care unit), HTN (hypertension), DM (diabetes mellitus), COPD (chronic obstructive pulmonary
503 disease).

504 **Table 2. AUC, cut-off, sensitivity and specificity**

| Antigen | Isotype | AUC | Cut-off | Sensitivity | Specificity |
|----------------|----------------|------------|----------------|--------------------|--------------------|
| RBD | IgG | 0.961 | 0.232 | 94% | 97% |
| | IgA | 0.974 | 0.112 | 97% | 94% |
| | IgM | 0.981 | 0.203 | 91% | 97% |
| Mpro | IgG | 0.994 | 0.161 | 97% | 100% |
| | IgA | 0.833 | 0.130 | 73% | 100% |
| | IgM | 0.859 | 0.237 | 79% | 79% |
| NP | IgG | 0.993 | 0.127 | 97% | 100% |
| | IgA | 0.949 | 0.066 | 88% | 94% |
| | IgM | 0.885 | 0.341 | 76% | 85% |

505 AUC, area under the curve; RBD, Receptor Binding Domain; Mpro, cysteine-like protease; NP, nucleoprotein

506

507

508

509 **Table 3. Variables that explain heterogeneity in antibody response against three proteins of**
 510 **SARS-CoV-2**

| | Mpro | | | | | | RBD | | | | | | NP | | | | | |
|----------------------------------|----------------|-------|----------------|--------------|----------------|--------------|----------------|-------|----------------|--------------|----------------|-------|----------------|-------|----------------|-------|----------------|-------|
| | IgG | | IgA | | IgM | | IgG | | IgA | | IgM | | IgG | | IgA | | IgM | |
| | β Coeff. | p | β Coeff. | p | β Coeff. | p | β Coeff. | p | β Coeff. | p | β Coeff. | p | β Coeff. | p | β Coeff. | p | β Coeff. | p |
| Age (year) | 0.010 | 0.013 | 0.021 | 0.085 | NRM | - | 0.007 | 0.083 | NRM | - | 0.008 | 0.037 | 0.009 | 0.039 | 0.016 | 0.092 | NRM | - |
| Time since symptoms onset (days) | NRM | - | -0.033 | 0.010 | -0.014 | 0.005 | NRM | - | -0.016 | 0.058 | -0.009 | 0.006 | NRM | - | -0.024 | 0.002 | -0.011 | 0.016 |
| Severity | Ref. | - | Ref. | - | Ref. | - | Ref. | - | Ref. | - | Ref. | - | Ref. | - | Ref. | - | - | - |
| Mild | -0.004 | 0.970 | 0.422 | 0.196 | 0.189 | 0.220 | 0.149 | 0.195 | -0.032 | 0.904 | 0.087 | 0.434 | 0.023 | 0.849 | 0.379 | 0.144 | 0.109 | 0.451 |
| Severe | -0.013 | 0.935 | 0.804 | 0.092 | 0.364 | 0.073 | 0.198 | 0.243 | 1.014 | 0.004 | 0.207 | 0.203 | 0.048 | 0.789 | 0.494 | 0.191 | 0.246 | 0.195 |

511 **Figure legends**

512 **Figure 1. SARS-CoV-2 protein purification.** Nucleocapsid (NP) (A) and Cys-like protease
513 (3CLpro, Mpro) (B) proteins were expressed in E. coli and extracted from the soluble fraction
514 of the bacterial pellet. The proteins were firstly purified by selection through their His-tags in
515 HiTrap Ni²⁺ chelating columns. The fractions eluted from these columns were run in SDS-
516 PAGE (top gels). After that, proteins were further purified by gel filtration using a Superdex 75
517 column and fractions eluted from this step were run in SDS-PAGE (bottom gels). The FPLC
518 profile is shown on the right panels. (C) mRBD The 334-528 fragment of the Spike protein was
519 produced in mammalian cells fused to an HA-tag, at the N-terminus and to the TIM-1 mucin
520 domain followed by the Fc portion of human IgG, at the C-terminus. Two thrombin-recognition
521 sites (asterisks) were introduced. The fusion protein was treated with thrombin (+T in the
522 SDS-PAGE shown at the right) to release the mRBD fragment. It was further purified using a
523 protein A column and size exclusion chromatography (Superdex 75). SDS-PAGE under
524 reducing conditions are shown for the samples at the purification steps. Proteins bound (B)
525 and unbound (U) to the protein A column are shown. (D) SDS-PAGE. After expression in the
526 different systems, proteins were purified and fractions from gel filtration chromatography were
527 run in SDS-PAGE under non reducing conditions.

528

529 **Figure 2. Detection of SARS-CoV-2 Mpro-specific antibodies by ELISA. (A) Sera titration**
530 **on Mpro.** Plates were coated with SARS-CoV-2 Mpro and sera dilutions (1/50 to 1/1600) were
531 tested. Detection was performed using anti-human F(ab)₂' antibody. (B) **Isotype recognition.**
532 Plates coated with SARS-CoV-2 Mpro, nucleoprotein (NP) and RBD were detected with
533 antibodies directed against human Ig of the three different subclasses: IgG, IgA, IgM. Black
534 symbols correspond to COVID-19 patients and grey symbols to donors pre-COVID-19. (C)
535 **Coating titration.** Plates were coated with increasing amounts of SARS-CoV-2 Mpro,
536 nucleoprotein (NP) and RBD and sera diluted 1/100 for IgG detection and 1/50 for IgA and
537 IgM were tested. Black symbols correspond to COVID-19 patients and grey symbols to donors
538 pre-COVID-19.

539

540 **Figure 3: Comparison of sera from 33 pre-COVID-19 vs 36 COVID-19 patients.** Plates
541 coated with either 0.5 or 1 µg/ml (as indicated) SARS-CoV-2 Mpro, NP or RBD were used to
542 perform ELISA tests on 36 COVID-19 positive and 33 negative control sera (obtained before
543 the pandemic outbreak, PRE-COVID-19). Detection was done using antibodies directed
544 against human immunoglobulin of the three different subclasses: IgG, IgA, IgM. Sera dilutions
545 from 1/50-1/3200 were carried out. Data were normalised for each antigen using the signal
546 obtained against a pool of positive sera. Box and whisker plots of all the sera tested at the

547 1/200 dilution for IgG and 1/50 for IgA and IgM. Statistical significance was analysed in Mann-
548 Whitney tests. **** means $p < 0.0001$.

549

550 **Figure 4: Assessment, through Receiver Operating Characteristic (ROC) analysis, of**
551 **different isotype responses against three SARS-CoV-2 proteins as COVID-19**
552 **classifiers.** Graphic representation of the relationship between sensitivity and specificity. The
553 area under the curve (AUC) calculated for each antigen and immunoglobulin pair (see
554 Statistical section of Material and Methods) is indicated. For details on specificity and
555 sensitivity data, see Supplementary Table 1.

556

557 **Figure 5. A. Correlations of humoral response against different SARS-CoV-2**
558 **antigens by isotype.** Data from Figure 2 are shown as dot-plots and their fitted
559 fractional polynomial prediction with 95% confidence interval (transparent grey
560 shadow) estimated using the two-way command of Stata with the `pfitted` option. **B.**
561 **Comparison of sera from mild, severe and critical patients.** Patients were classified into
562 three groups (mild $n=13$, severe $n=17$ and critical $n=6$) according to COVID-19 symptoms
563 severity (see reference 13). Data normalised for each antigen using the signal obtained
564 against a pool of positive sera obtained in Figure 2, are depicted in box and whisker plots at
565 the 1/200 dilution for IgG and 1/50 for IgA and IgM. Statistical significance was analysed by
566 Cuzick's test.

567

568 **Figure 6. No cross-reactivity is observed between proteins from SARS-Cov-2 and OC43**
569 **betacoronaviruses.** Plates were coated with 0.5 $\mu\text{g/ml}$ of either SARS-CoV-2 NP or OC43
570 NP as indicated. Sera collected before 2020 (Pre-COVID-19) were tested at a 1/100 dilution.
571 Detection was performed using antibody directed against human IgG. The bars labelled "2721-
572 0848" correspond to COVID-19 PCR+ sera; the wells in which the amount of coated protein
573 was tested by incubation with either anti-His are indicated. 13 out of 20 (65%) pre-COVID sera
574 and 4 out of 7 (57%) COVID-19+ were clearly seropositive for OC43 NP. The donors with
575 higher titres for OC43 anti-NP antibodies do not respond against SARS-NP, indicating that
576 prior infection with OC43 does not lead to generation of antibodies reactive with SARS-CoV-
577 2 antigens.


578

579 **Figure 7: Comparison of saliva from healthy donors and 12 COVID-19 seropositive**
580 **individuals.** Plates coated with either 0.5 $\mu\text{g/ml}$ of SARS-CoV-2 Mpro and NP or 1 $\mu\text{g/ml}$ of


581 RBD and ELISA tests were carried out on saliva samples diluted 1/2 to 1/10. Detection was
582 done using antibodies directed against human IgG. Data were normalised for each antigen
583 using the signal obtained for the positive control histidine-tag. Mann-Whitney test was
584 performed to compare the values obtained for each dilution in healthy donors and patients. **
585 $p < 0.01$, **** $p < 0.0001$.

586



A. NP




B. Mpro




C. mRBD




D. SDS-PAGE of purified proteins



A. ELISA. Coating Mpro / Detection anti-h F(ab)2'



B. Detection with anti-human IgG, IgA, IgM



C. Coating titration

Figure 2






Figure 3

Mpro (0.5 µg/ml)



RBD (1 µg/ml)



NP (0.5 µg/ml)






Figure 4

Mpro (0.5 µg/ml)


IgG



IgA




IgM




RBD (1 µg/ml)


IgG



IgA




IgM




NP (0.5 µg/ml)


IgG




IgA



IgM



A. Antigen comparison



B. Severity comparison




Figure 6








Figure 7






Supplementary Figure 1. Detection of SARS-CoV-2 RBD-specific antibodies by ELISA. Plates were coated with SARS-CoV-2 RBD proteins produced in eukaryotic systems, either using insect or mammalian cells, and sera dilutions (1/100 to 1/1600) were tested. Detection was performed using anti-human IgG antibody. Black symbols correspond to COVID-19 patients and grey symbols to samples from donors pre-COVID-19.

A. Serum background in plates coated with casein (no viral protein)




B. Sera collected before 2020 (pre-COVID-19)



Supplementary Figure 2. Background levels and negative ontrols. A. Background in plates with no viral protein coating. Plates were coated with 1 $\mu\text{g/ml}$ of SARS-CoV-2 Mpro or iRBD and different dilutions of patient sera, as indicated, and detected with anti-human F(ab) $2'$ antibody (left and middle panels). Casein control corresponds to wells coated with the blocking solution, containing casein (right). These wells were incubated with the same sera and developed with anti-human F(ab) $2'$ antibody to check the background corresponding to individual sera. **B. SARS-CoV-2 negative ontrols.** 24 sera collected before 2020 (Pre-COVID-19) were tested in plates coated with 1 $\mu\text{g/ml}$ of SARS-CoV-2 Mpro or NP. Sera were added at a 1/50-1/900 dilution. Detection was performed using antibodies directed against human IgG or IgM. Data from the 1/50 dilution are shown for IgM and 1/200 for IgG. Serum number 0850 corresponds to a positive ontrol serum.

A. Mpro












B. RBD


IgG

IgA

IgM



C. NP



Supplementary Figure 3: Comparisons between different sera dilutions for RBD, Mpro and NP. Plates coated with SARS-CoV-2 Mpro, NP or RBD were used to perform ELISA tests on 36 COVID-19 positive and 33 negative control sera. Detection was done using antibodies directed against human immunoglobulin of the three different subclasses: dilutions 1/50-1/3200 were used for IgG; dilutions 1/50-1/1350 were used for IgA and IgM. Graphs represent data of the ODs obtained for each antigen and each donor, after normalising the signal against a pool of positive sera. **A. Mpro. B. RBD. C. NP.**

A. Aminoacid alignment of Mpro from different human coronaviruses

| | | |
|------------|--|-----|
| HCoVNL63 | SGLKKMAQPSGCVVERCVVRCYGSTVLNGVWLGDTVTCPRHVIAPSTTV-LIDYDHAYST | 59 |
| HCoV229E | AGLRKMAQPSGFVEKCVVRVVCYGNTVLNGLWLGDIVYCPRHVIASNTTS-AIDYDHEYSI | 59 |
| SARS-CoV-2 | -GFRKMAFPSPGKVEGCMVQVTCGTTTLNGLWLDVVYCPRHVICTSEDMLNPNYEDLLIR | 59 |
| HCoVOC43 | SGIVKMVNPTSKEVEPCVVSVTYGNMTLNGLWLDKVKYCPRHVICASDMTNPDYTNLLCR | 60 |
| | *: ** . *: . ** *: * * * . .***:** * ***** . :* . | |
| HCoVNL63 | MRLHNFVSHNGVFLGVVGMTMHGSVLRIKVVSQSNVHTPKHVFKTLKPGDSFNILACYEG | 119 |
| HCoV229E | MRLHNFIIISGTAFLGVVGMTMHGVTLKIKVVSQTNMHTPRHSFRTLKSGEGFNILACYDG | 119 |
| SARS-CoV-2 | KSNHNFVQAGNVQLRVIGHSMQNCVLKLVDTANPKTPKYKRVRIQPGQTFVSVLACYNG | 119 |
| HCoVOC43 | VTSSDFTVLFDRLSLTVMYSQMRGCMVLVTLVTLQNSRTPKYTFGVVKPGETFTVLAAAYNG | 120 |
| | :* : . * *: . *: . * :.* * :***: * :: *: * :***:*** | |
| HCoVNL63 | IASGVFGVNLRTNFTIKGSFINGACGSPGYNVRNDGTVEFCYLHQIELGSGAHVGSDFGTG | 179 |
| HCoV229E | CAQGVFGVNMRTNWTIRGSFINGACGSPGYNLKN-GEVEFVYMHQIELGSGSHVGSDFDG | 178 |
| SARS-CoV-2 | SPSGVYQCAMRPNFTIKGSFLNGSCGSGVGFNIDY-DCVSFCYMHMELPTGVHAGTDLEG | 178 |
| HCoVOC43 | KPQGAHVMTMRSSYTIKGSFLCGSCGSGVGYVIMG-DCVKFVYMHQLELSTGCHTGTDFNG | 179 |
| | .*: . :* .:***:**: *:** * : : . *.* *:*:*:* * *.*: : * | |
| HCoVNL63 | SVYGNFDDQPSLQVESANLMLSDNVVAFLYAALLNGCRWWLCSTRVNVDFGNEWAMANGY | 239 |
| HCoV229E | VMYGGFEDQPNLQVESANQMLTVNVVAFLYAAILNGCTWWLKGEKLFVEHYNEWAQANGF | 238 |
| SARS-CoV-2 | NFYGPFVDRQTAQAAGTDTTITVNVLAFLYAAVINGDRWFLNREFTTTLNDFNLVAMKYNV | 238 |
| HCoVOC43 | DFYGPYKDAQVVLPIQDYIQSVNFWLAWLYAAILNNCNWFIQSDKCSVEDFNWVWALSNGF | 239 |
| | .** : * * : : *.:**:**:**. *:: : : * * .: | |
| HCoVNL63 | TSVSSVE--CYSILAAKTGVSVQQLLASI-QHLHEGFGGKNI LGYSSLCDEFTLAEVVKQ | 296 |
| HCoV229E | TAMNGED--AFSILAAKTGVCVERLLHAI-QVLNNGFGGKQILGYSSLNDEF SINEVVKQ | 295 |
| SARS-CoV-2 | EPLTQDHDVLDLGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALEDEF TPFVVRQ | 298 |
| HCoVOC43 | SQVKSIDLV--IDALASMTGVSLETLLAAI-KRLKNGFQGRQIMGSCSFEDELTPSDVYQQ | 296 |
| | :. . *:: **::: : : : *::* * : *.* . : **:: :* :* | |
| HCoVNL63 | MYGVNLQ | 303 |
| HCoV229E | MFGVNLQ | 302 |
| SARS-CoV-2 | CSGVTFQ | 305 |
| HCoVOC43 | LAGIKLQ | 303 |
| | *: . : * | |

Supplementary Figure 4. Alignment of Mpro amino acid sequences from the indicated coronaviruses. Sequences were obtained from the NCBI database and aligned using the Clustal Omega program (<https://www.ebi.ac.uk/Tools/msa/clustalo/>). * indicates positions which have a single, fully conserved residue, : indicates strong similarity, . indicates weak similarity.